P057: TLD-1, a Second-Generation Nano-Liposomal Doxorubicin, in Patients with Advanced Breast Cancer from the Dose Escalation and Expansion Phase 1 Study (SAKK 65/16)

• DOI: 10.1016/j.breast.2025.103907
• Publication Date: 2025-03-10T11:01:41Z
• Authors: M. Rabaglio-Poretti; K.-L. Koster; K. Gobat; S. Haefliger; I. Colombo; S. Bastian; M. Schwitter; K. Eckhardt; S. Hayoz; S. Halbherr; B. Thürlimann; C. Sessa; A. Stathis; D. Hess; M Joerger